Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

3 results

  • Chapter 29 - In Vitro Growth of Human Oocytes
  • from Section 8 - In Vitro Follicle Culture
  • Edited by Jacques Donnez, S. Samuel Kim
  • Book: Fertility Preservation
  • Published online: 27 March 2021
  • Print publication: 08 April 2021, pp 332-340
  • View extract

    Summary

    Patients with cancer who desire to preserve their future reproductive potential but require immediate gonadotoxic treatments (chemo and/or radiotherapy) are left with few options for fertility preservation. These options include (a) cryopreservation of ovarian tissues as cortical strips; (b) dual cryopreservation of both ovarian cortical tissue and cryopreservation, after in vitro maturation, of immature oocytes extracted from the small antral follicles visible within the ovarian cortex at the time of the harvest; and (c) cryopreservation of one whole ovary [1–9]. At the time of this writing, each of these options is still considered experimental by the American Society of Reproductive Medicine (thus requiring institutional review board approval and patient’s informed consent), although it is expected that soon ovarian tissue cryopreservation will no longer be considered experimental.

  • Chapter 33 - In vitro growth systems for human oocytes
  • from Section 8 - In vitro follicle growth and maturation
  • Edited by Jacques Donnez, Université Catholique de Louvain, Belgium, S. Samuel Kim, University of Kansas
  • Book: Principles and Practice of Fertility Preservation
  • Published online: 04 February 2011
  • Print publication: 03 February 2011, pp 397-408
  • View abstract

    Summary

    Ovarian cancers are classified as epithelial (including borderline and malignant tumors) and non-epithelial cancers. The standard treatment of borderline ovarian tumours (BOT) consisted of a total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, omentectomy and multiple peritoneal biopsies. The differential criterion between epithelial ovarian cancer (EOC) and BOT is the invasion of the ovarian stroma. The standard surgical procedure for EOC is a radical hysterectomy with bilateral salpingo-oophorectomy. Non-epithelial malignant tumors are characterized by: the occurrence of disease in younger patients; and a good prognosis of this tumor. Conservative treatment yields good fertility results and does not affect the survival of patients with BOT. It should be considered for young women desiring fertility, even if peritoneal implants are discovered at the time of initial surgery. In case of infertility, medically-assisted procreation techniques may be proposed to patients with stage I BOT with a limited number of stimulation cycles.